Thromboembolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Thromboembolism represents a significant complication arising from catheter ablation procedures despite its relatively low incidence in most cardiac arrhythmias. The overall risk of thromboembolism is approximately 0.6%, but it increases to 1.8%–2.0% in left-sided procedures. Thrombi may form on intravascular sheaths, radiofrequency (RF) lesions can be inherently thrombogenic, and preexisting thrombi may become dislodged. Most thromboembolic events occur within 24 hours post-ablation, with a heightened risk period extending to two weeks. While cerebral thromboembolism is most frequently identified clinically, emboli can also affect the pulmonary artery, coronary artery, or abdominal and peripheral vascular circulation. Management of cerebral embolism can be conservative or involve thrombolytic therapy or percutaneous intervention. Preventative measures for thromboembolism associated with catheter ablation include appropriate anticoagulation, optimal RF energy settings, external irrigation catheters, and continuous irrigation with heparinized saline through the sheaths. Thromboembolism is a significant cause of morbidity and mortality, leading to conditions such as stroke, pulmonary embolism, and acute limb ischemia. Long-term complications of adequately treated venous thromboembolism (VTE) are rare, with post-thrombotic syndrome being the most commonly reported. This syndrome typically presents as pain and swelling of the limb, accompanied by chronic venous insufficiency.
Thelansis’s “Thromboembolism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thromboembolism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Thromboembolism across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Thromboembolism Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment